24/7 Market News Snapshot 23 April, 2025 – Candel Therapeutics, Inc. Common Stock (NASDAQ:CADL)

April 23, 2025

DENVER, Colo., 23 April, 2025 (www.247marketnews.com) – (NASDAQ:CADL) are discussed in this article.
Candel Therapeutics, Inc. (CADL) is experiencing notable momentum in the stock market, opening at $5.00 and trading up to $5.40, marking an impressive increase of 14.04% from its previous close of $4.735. This surge in stock value indicates a growing investor interest, reinforced by a trading volume of 1.34 million shares. The stock’s recent breakout above key resistance levels signals potential for further upward movement, although traders are advised to remain cautious due to the possibility of volatility in the biotech sector.

In a significant development, Candel Therapeutics announced that a pivotal abstract highlighting advancements in its cancer immunotherapy research has been accepted for oral presentation at the upcoming 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 30 to June 3, 2025. The presentation will focus on results from a phase 3 clinical trial examining CAN-2409, an innovative multimodal biological immunotherapy aimed at patients with intermediate-to-high-risk localized prostate cancer.

Scheduled for June 3, 2025, the presentation will be led by Dr. Theodore DeWeese, a prominent expert in the field and Dean of the Medical Faculty at Johns Hopkins Medicine. The study, titled “Phase 3, randomized, placebo-controlled clinical trial of CAN-2409+prodrug in combination with standard-of-care external beam radiation therapy for newly diagnosed localized prostate cancer,” underlines Candel’s commitment to advancing cancer treatment.

CAN-2409 represents a novel approach that leverages the herpes simplex virus thymidine kinase (HSV-tk) gene to facilitate a targeted immune response against tumors. Preliminary results from prior trials have indicated that CAN-2409 not only meets primary objectives but also maintains a favorable safety profile across various cancer types. Candel’s ongoing dedication to pioneering advancements in immunotherapy aims to deliver more effective, personalized treatment options for patients battling cancer globally.

Related news for (CADL)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.